Diabetes does not influence activation of coagulation, fibrinolysis or anticoagulant pathways in Gram-negative sepsis (melioidosis)

Summary

Diabetes is associated with a disturbance of the haemostatic balance and is an important risk factor for sepsis, but the influence of diabetes on the pathogenesis of sepsis remains unclear. Melioidosis (Burkholderia pseudomallei infection) is a common cause of community-acquired sepsis in Southeast Asia and northern Australia. We sought to investigate the impact of pre-existing diabetes on the coagulation and fibrinolytic systems during sepsis caused by B. pseudomallei. We recruited a cohort of 44 patients (34 with diabetes and 10 without diabetes) with culture-proven melioidosis. Diabetes was defined as a pre-admission diagnosis of diabetes or an HbA_1c>7.8% at enrolment. Thirty healthy blood donors and 52 otherwise healthy diabetes patients served as controls. Citrated plasma was collected from all subjects; additionally in melioidosis patients follow-up specimens were collected seven and ≥28 days after enrolment where possible. Relative to uninfected healthy controls, diabetes per se (i.e. in the absence of infection) was Characterised by a procoagulant effect. Melioidosis was associated with activation of coagulation (thrombin-antithrombin complexes (TAT), prothrombin fragment F₁₊₂ and fibrinogen concentrations were elevated; PT and PTT prolonged), suppression of anti-coagulation (antithrombin, protein C, total and free protein S levels were depressed) and abnormalities of fibrinolysis (D-dimer and plasmin-antiplasmin complex [PAP] were elevated). Remarkably, none of these haemostatic alterations were influenced by pre-existing diabetes. In conclusion, although diabetes is associated with multiple abnormalities of coagulation, anticoagulation and fibrinolysis, these changes are not detectable when superimposed on the background of larger abnormalities attributable to B. pseudomallei sepsis.

Keywords

Diabetes mellitus - Burkholderia pseudomallei - melioidosis - coagulation - fibrinolysis

• References

• 1 Kinasewitz GT, Yan SB, Basson B. et al. Universal changes in biomarkers of coagulation and inflammation occur in patients with severe sepsis, regardless of causative micro-organism. Crit Care 2004; 8: R82-90.
• 2 Levi M, van der Poll T, Büller HR. Bidirectional relation between inflammation and coagulation. Circulation 2004; 109: 2698-2704.
• 3 Esper A, Moss M, Martin G. The effect of diabetes mellitus on organ dysfunction with sepsis: an epidemiological study. Critical Care 2009; 13: R18
• 4 Stegenga ME, Vincent J-L, Vail GM. et al. Diabetes does not alter mortality or hemostatic and inflammatory responses in patients with severe sepsis. Crit Care Med 2010; 38: 539-545.
• 5 Stegenga ME, van der Crabben SN, Levi M. et al. Hyperglycemia stimulates coagulation, whereas hyperinsulinemia impairs fibrinolysis in healthy humans. Diabetes 2006; 55: 1807-1812.
• 6 Stegenga ME, van der Crabben SN, Blümer RME. et al. Hyperglycemia enhances coagulation and reduces neutrophil degranulation, whereas hyperinsulinemia inhibits fibrinolysis during human endotoxemia. Blood 2008; 112: 82-89.
• 7 Vardakas KZ, Siempos I I, Falagas ME. Diabetes mellitus as a risk factor for nosocomial pneumonia and associated mortality. Diabet Med 2007; 24: 1168-1171.
• 8 Tsai CL, Lee CC, Ma MH. et al. Impact of diabetes on mortality among patients with community-acquired bacteremia. J Infect 2007; 55: 27-33.
• 9 Thomsen RW, Hundborg HH, Lervang H-H. et al. Diabetes and outcome of community-acquired pneumococcal bacteremia: a 10-year population-based cohort study. Diabetes Care 2004; 27: 70-76.
• 10 Haug JB, Harthug S, Kalager T. et al. Bloodstream infections at a Norwegian university hospital, 1974-1979 and 1988-1989: changing etiology, clinical features, and outcome. Clin Infect Dis 1994; 19: 246-256.
• 11 Kornum JB, Thomsen RW, Riis A. et al. Type 2 diabetes and pneumonia outcomes: a population-based cohort study. Diabetes Care 2007; 30: 2251-2257.
• 12 Thomsen RW, Hundborg HH, Lervang H-H. et al. Diabetes mellitus as a risk and prognostic factor for community-acquired bacteremia due to enterobacteria: a 10-year, population-based study among adults. Clin Infect Dis 2005; 40: 628-631.
• 13 Graham BB, Keniston A, Gajic O. et al. Diabetes mellitus does not adversely affect outcomes from a critical illness. Crit Care Med 2010; 38: 16-24.
• 14 Wuthiekanun V, Peacock SJ. Management of melioidosis. Expert Rev Anti Infect Ther 2006; 4: 445-455.
• 15 Currie BJ, Fisher DA, Howard DM. et al. Endemic melioidosis in tropical northern Australia: a 10-year prospective study and review of the literature. Clin Infect Dis 2000; 31: 981-986.
• 16 White NJ. Melioidosis. Lancet 2003; 361: 1715-1722.
• 17 Suputtamongkol Y, Rajchanuwong A, Chaowagul W. et al. Ceftazidime vs. amoxicillin/clavulanate in the treatment of severe melioidosis. Clin Infect Dis 1994; 19: 846-853.
• 18 Currie BJ, Ward L, Cheng AC. The epidemiology and clinical spectrum of melioidosis: 540 cases from the 20 year Darwin prospective study. PLoS Negl Trop Dis 2010; 4: e900
• 19 Koh GCKW, Maude RR, Schreiber MF. et al. Glyburide is anti-inflammatory and associated with reduced mortality in melioidosis. Clin Infect Dis 2011; 52: 717-725.
• 20 Suputtamongkol Y, Chaowagul W, Chetchotisakd P. et al. Risk factors for melioidosis and bacteremic melioidosis. Clin Infect Dis 1999; 29: 408-413.
• 21 Lo TJ, Ang LW, James L. et al. Melioidosis in a tropical city state, Singapore. Emerging Infect Dis 2009; 15: 1645-1647.
• 22 Cheng AC, Currie BJ. Melioidosis: epidemiology, pathophysiology, and management. Clin Microbiol Rev 2005; 18: 383-416.
• 23 Wiersinga WJ, Meijers JCM, Levi M. et al. Activation of coagulation with concurrent impairment of anticoagulant mechanisms correlates with a poor outcome in severe melioidosis. J Thromb Haemost 2008; 6: 32-39.
• 24 Limmathurotsakul D, Wuthiekanun V, Chierakul W. et al. Role and significance of quantitative urine cultures in diagnosis of melioidosis. J Clin Microbiol 2005; 43: 2274-2276.
• 25 Levy MM, Fink MP, Marshall JC. et al. 2001 SCCM/ESICM/ACCP/ATS/SIS International Sepsis Definitions Conference. Crit Care Med 2003; 31: 1250-1256.
• 26 McCane DR, Hanson RL, Charles MA. et al. Comparison of tests for glycated haemoglobin and fasting and two hour plasma glucose concentrations as diagnostic methods for diabetes. Br Med J 1994; 308: 1323-1328.
• 27 World Health Organization. Part 1: Diagnosis and classification of diabetes mellitus. In Definition, diagnosis and classification of diabetes mellitus and its complications. Geneva: World Health Organization; 1999
• 28 Hemker HC, Béguin S. Thrombin generation in plasma: its assessment via the endogenous thrombin potential. Thromb Haemost 1995; 74: 134-138.
• 29 Voves C, Wuillemin WA, Zeerleder S. International Society on Thrombosis and Haemostasis score for overt disseminated intravascular coagulation predicts organ dysfunction and fatality in sepsis patients. Blood Coagul Fibrinolysis 2006; 17: 445-451.
• 30 de Pont A-CJM, Bakhtiari K, Hutten BA. et al. Endotoxaemia induces resistance to activated protein C in healthy humans. Br J Haematol 2006; 134: 213-219.
• 31 Aso Y, Matsumoto S, Fujiwara Y. et al. Impaired fibrinolytic compensation for hypercoagulability in obese patients with type 2 diabetes: Association with increased plasminogen activator inhibitor-1. Metabolism 2002; 51: 471-476.
• 32 Ceriello A. Coagulation activation in diabetes mellitus: the role of hyperglycaemia and therapeutic prospects. Diabetologia 1993; 36: 1119-1125.
• 33 Grant PJ. Diabetes mellitus as a prothrombotic condition. J Intern Med 2007; 262: 157-172.
• 34 Rao AK, Chouhan V, Chen X. et al. Activation of the tissue factor pathway of blood coagulation during prolonged hyperglycemia in young healthy men. Diabetes 1999; 48: 1156-1161.
• 35 LaRosa SP, Opal SM, Utterback B. et al. Decreased protein C, protein S, and antithrombin levels are predictive of poor outcome in Gram-negative sepsis caused by Burkholderia pseudomallei. Int J Infect Dis 2006; 10: 25-31.
• 36 Bernard GR, Vincent JL, Laterre PF. et al. Efficacy and safety of recombinant human activated protein C for severe sepsis. N Engl J Med 2001; 344: 699-709.
• 37 Dahlbäck B, Carlsson M, Svensson PJ. Familial thrombophilia due to a previously unrecognized mechanism characterized by poor anticoagulant response to activated protein C: prediction of a cofactor to activated protein C. Proc Natl Acad Sci USA 1993; 90: 1004-1008.
• 38 Bertina RM, Koeleman BP, Koster T. et al. Mutation in blood coagulation factor V associated with resistance to activated protein C. Nature 1994; 369: 64-67.
• 39 Henkens CM, Bom VJ, van der Meer J. Lowered APC-sensitivity ratio related to increased factor VIII-clotting activity. Thromb Haemost 1995; 74: 1198-1199.
• 40 de Ronde H, Bertina RM. Laboratory diagnosis of APC-resistance: a critical evaluation of the test and the development of diagnostic criteria. Thromb Haemost 1994; 72: 880-886.
• 41 Kilpatrick ES, Bloomgarden ZT, Zimmet PZ. Is haemoglobin A1c a step forward for diagnosing diabetes?. Br Med J 2009; 339: b4432